4-氨基-2,3-二甲基-苯酚盐酸盐(1:1) | 94276-04-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 4-氨基-2,3-二甲基-苯酚盐酸盐(1:1)
• 中文别名: 肼碳杂氧杂脒,N-甲基-1-[2-(4-甲基-1-哌啶基)乙基]-
• 英文名称: 4-amino-2,3-dimethyl-1-hydroxybenzene hydrochloride
• 英文别名: 4-amino-2,3-dimethylphenol, hydrochloride；4-Amino-2,3-dimethylphenol hydrochloride；4-Amino-2,3-xylenol hydrochloride；4-amino-2,3-dimethylphenol;hydrochloride
• CAS: 94276-04-7
• 化学式: C₈H₁₁NO*ClH
• 分子量: 173.642
• InChiKey: GXLRCJUNACHBAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.01
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.2
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-氨基-2,3-二甲基-苯酚盐酸盐(1:1) 在 咪唑 、 盐酸 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 N-(4-hydroxy-2,3-dimethyl-phenyl)acetamide
  参考文献：
  名称：

  The fischer indolisation reaction and the synthesis of dihydroindenoindoles

  摘要：

  The Fischer reaction between indanones and certain alkoxyarylhydrazines fails; the indanones are returned unreacted and the arylhydrazines are converted into the corresponding alkoxy-2-chloroarylamines and other products. A new N-amination route to arylhydrazines from the arylamines has been developed and it has been demonstrated that problems with the indolisation of alkoxyarylhydrazones can be circumvented by ring closures of their O-tosylated analogues. Some results using the Lepke synthesis of indoles are recorded.

  DOI：

  10.1016/s0040-4020(01)81911-6

文献信息

• 2-(hydroxy-2-alkylphenylamino)-oxazolines and thiazolines as
  申请人：Allergan, Inc.

  公开号：US05066664A1

  公开（公告）日：1991-11-19

  Compounds of the formula ##STR1## where X is O or S; R.sub.1 is lower alkyl having 1 to 6 carbons; R.sub.2 is H, lower alkyl having 1 to 6 carbons; or OR.sub.2.sup.* where R.sub.2.sup.* is lower alkyl having 1 to 6 carbons; Y is O, S or NH; and R.sub.3 is H, lower alkyl having 1 to six carbons, or C(O)R.sub.3.sup.* where R.sub.3.sup.* is lower alkyl having 1 to 5 carbons, with the proviso that the YR.sub.3 group is not disposed in the ortho position on the benzene nucleus relative to the 2-amino group of the oxazoline or thiazoline heterocycle, are active in maintaining or reducing intraocular pressure in the mammalian eye, and are active as vasoconstrictors and capable of reducing or controlling intraocular bleeding of the mammalian eye.

  化合物的公式为##STR1##其中X为O或S; R.sub.1是具有1至6个碳的低烷基; R.sub.2是H，具有1至6个碳的低烷基; 或OR.sub.2.sup.*其中R.sub.2.sup.*是具有1至6个碳的低烷基; Y为O，S或NH; R.sub.3为H，具有1至六个碳的低烷基，或C(O)R.sub.3.sup.*其中R.sub.3.sup.*是具有1至5个碳的低烷基，但YR.sub.3基团不得相对于噁唑啉或噻唑啉杂环的2-氨基位于苯环核的邻位，这些化合物在维持或降低哺乳动物眼内压方面具有活性，并且在缩血管和减少或控制哺乳动物眼内出血方面具有活性。
• Quinoline derivatives and quinazoline derivatives
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：US20040209905A1

  公开（公告）日：2004-10-21

  An object of the present invention is to provide compounds which have antitumor activity and do not change cytomorphosis. Disclosed are compounds represented by formula (I) and a pharmaceutically acceptable salts and solvates thereof and pharmaceutical compositions comprising said compounds: 1 wherein X and Z each independently represent CH or N; R 1 to R 3 represent H, substituted alkoxy, unsubstituted alkoxy or the like; R 4 represents H; R 5 to R 8 represent H, halogen, alkyl, alkoxy, alkylthio, nitro, or amino, provided that R 5 to R 8 do not simultaneously represent H; R 9 and R 10 represent H, alkyl, or alkylcarbonyl; and R 11 represents alkyl, alkenyl, alkynyl, or aralkyl.

  本发明的目的是提供具有抗肿瘤活性且不改变细胞形态的化合物。本发明揭示了由式（I）表示的化合物，以及其药学上可接受的盐和溶剂和包含所述化合物的制药组合物：1其中X和Z各自独立地表示CH或N; R1至R3表示H、取代烷氧基、未取代烷氧基或类似物; R4表示H; R5至R8表示H、卤素、烷基、烷氧基、烷基硫基、硝基或氨基，但要求R5至R8不同时表示H; R9和R10表示H、烷基或烷基羰基; 而R11表示烷基、烯基、炔基或芳基烷基。
• Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1384712A1

  公开（公告）日：2004-01-28

  An object of the present invention is to provide compounds which have antitumor activity and do not change cytomorphosis. Disclosed are compounds represented by formula (I) and a pharmaceutically acceptable salts and solvates thereof and pharmaceutical compositions comprising said compounds: wherein X and Z each independently represent CH or N; R1 to R3 represent H, substituted alkoxy, unsubstituted alkoxy or the like; R4 represents H; R5 to R8 represent H, halogen, alkyl, alkoxy, alkylthio, nitro, or amino, provided that R5 to R8 do not simultaneously represent H; R9 and R10 represent H, alkyl, or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl, or aralkyl.

  本发明的目的是提供具有抗肿瘤活性且不改变细胞形态的化合物。本发明公开了式(I)代表的化合物及其药学上可接受的盐和溶液以及包含所述化合物的药物组合物： 其中X和Z各自独立地代表CH或N；R1至R3代表H、取代的烷氧基、未取代的烷氧基或类似物；R4代表H；R5至R8代表H、卤素、烷基、烷氧基、烷硫基、硝基或氨基，但R5至R8不同时代表H；R9和R10代表H、烷基或烷基羰基；R11代表烷基、烯基、炔基或芳烷基。
• QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1153920B1

  公开（公告）日：2003-10-29
• US6797823B1
  申请人：——

  公开号：US6797823B1

  公开（公告）日：2004-09-28

表征谱图